Effect of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy
RecruitingNot applicableNCT06778460
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is a further observation and follow-up of the patients enrolled in the registration number ChiCTR230007164430 to further evaluate the effect of long-term infusion of esketamine and lidocaine on postoperative chronic pain, long-term quality of life and survival rate in patients undergoing hepatectomy.
Study details
- Official title
- Effect of Perioperative Continuous Intravenous Infusion of Esketamine and Lidocaine on Postoperative Chronic Pain and Long-term Survival in Patients Undergoing Hepatectomy
- Conditions
- Postoperative Chronic Pain
- Interventions
- Drug: Esketamine-lidocaine group
- Other: Placebo group
- Sponsor
- West China Hospital
- Start date
- 2023-05-05
- Primary completion
- 2027-03-31
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Aged 18-75 years; 2. Scheduled for elective hepatectomy; 3. ASA grade I-III. Exclusion Criteria: 1. Patients who have been intubated in the ICU following surgery and do not have a planned extubation within 6 hours postoperatively. 2. Patients with a body weight less than 40 kg or greater than 100 kg. 3. Patients with cardiac conduction system abnormalities (second- or third-degree atrioventricular block) or cardiac insufficiency (left ventricular ejection fraction \< 50%). 4. Patients with severe hepatic insufficiency (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], or bilirubin levels more than 2.5 times the upper limit of normal) or renal insufficiency (creatinine clearance rate \< 60 mL/min). 5. Patients with a known hypersensitivity to the investigational drug. 6. Patients with a history of long-term opioid abuse. 7. Patients who are unable to communicate effectively. 8. Patients with serious comorbid medical conditions, such as uncontrolled hypertension, coronary heart disease, intracranial vascular malformations, or acute asthma exacerbations. 9. Patients with a history of epilepsy or a history of manic episodes. 10. Pregnant or breastfeeding women. 11. Patients with glaucoma. 12. Patients with preoperative cognitive dysfunction, bipolar disorder, or other psychiatric disorders, including mental retardation. 13. Patients with primary liver cancer in conjunction with malignant tumors of other organs (such as lung, kidney, intestine, etc.), or those with clinical symptoms or imaging findings suggestive of distant metastasis.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06778460